ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer Drug based on PARP Inhibitor Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-3P7754
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Cancer Drug based on PARP Inhibitor Market Insights Forecast to 2028
BUY CHAPTERS

Global Cancer Drug based on PARP Inhibitor Market Research Report 2025

Code: QYRE-Auto-3P7754
Report
July 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Merck
GSK
Clovis Oncology
Pfizer Inc
ZAI LAB

Cancer Drug based on PARP Inhibitor Market Size

The global market for Cancer Drug based on PARP Inhibitor was valued at US$ 8441 million in the year 2024 and is projected to reach a revised size of US$ 15210 million by 2031, growing at a CAGR of 8.9% during the forecast period.

Cancer Drug based on PARP Inhibitor Market

Cancer Drug based on PARP Inhibitor Market

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP)
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cancer Drug based on PARP Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug based on PARP Inhibitor.
The Cancer Drug based on PARP Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Drug based on PARP Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Drug based on PARP Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Cancer Drug based on PARP Inhibitor Market Report

Report Metric Details
Report Name Cancer Drug based on PARP Inhibitor Market
Accounted market size in year US$ 8441 million
Forecasted market size in 2031 US$ 15210 million
CAGR 8.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Lynparza
  • Zejula
  • Rubraca
  • Talzenna
Segment by Application
  • Ovarian Cancer
  • Breast Cancer
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Merck & Co, GSK, Clovis Oncology, Pfizer, Zai Lab
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Cancer Drug based on PARP Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Cancer Drug based on PARP Inhibitor Market growing?

Ans: The Cancer Drug based on PARP Inhibitor Market witnessing a CAGR of 8.9% during the forecast period 2025-2031.

What is the Cancer Drug based on PARP Inhibitor Market size in 2031?

Ans: The Cancer Drug based on PARP Inhibitor Market size in 2031 will be US$ 15210 million.

Who are the main players in the Cancer Drug based on PARP Inhibitor Market report?

Ans: The main players in the Cancer Drug based on PARP Inhibitor Market are AstraZeneca, Merck & Co, GSK, Clovis Oncology, Pfizer, Zai Lab

What are the Application segmentation covered in the Cancer Drug based on PARP Inhibitor Market report?

Ans: The Applications covered in the Cancer Drug based on PARP Inhibitor Market report are Ovarian Cancer, Breast Cancer, Other

What are the Type segmentation covered in the Cancer Drug based on PARP Inhibitor Market report?

Ans: The Types covered in the Cancer Drug based on PARP Inhibitor Market report are Lynparza, Zejula, Rubraca, Talzenna

Recommended Reports

Cancer Therapy Drugs

Targeted Oncology Inhibitors

Cancer Type Drug Markets

1 Cancer Drug based on PARP Inhibitor Market Overview
1.1 Product Definition
1.2 Cancer Drug based on PARP Inhibitor by Type
1.2.1 Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2024 VS 2031)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.3 Cancer Drug based on PARP Inhibitor by Application
1.3.1 Global Cancer Drug based on PARP Inhibitor Market Value by Application (2024 VS 2031)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global Cancer Drug based on PARP Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Cancer Drug based on PARP Inhibitor Revenue 2020-2031
1.4.2 Global Cancer Drug based on PARP Inhibitor Sales 2020-2031
1.4.3 Global Cancer Drug based on PARP Inhibitor Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Cancer Drug based on PARP Inhibitor Market Competition by Manufacturers
2.1 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2020-2025)
2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Cancer Drug based on PARP Inhibitor Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Cancer Drug based on PARP Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Date of Enter into This Industry
2.8 Global Cancer Drug based on PARP Inhibitor Market Competitive Situation and Trends
2.8.1 Global Cancer Drug based on PARP Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Cancer Drug based on PARP Inhibitor Players Market Share by Revenue
2.8.3 Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Cancer Drug based on PARP Inhibitor Market Scenario by Region
3.1 Global Cancer Drug based on PARP Inhibitor Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2020-2031
3.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2020-2025
3.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2026-2031
3.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2020-2031
3.3.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2020-2025
3.3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2026-2031
3.4 North America Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country
3.4.1 North America Cancer Drug based on PARP Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Cancer Drug based on PARP Inhibitor Sales by Country (2020-2031)
3.4.3 North America Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country
3.5.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2020-2031)
3.5.3 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Drug based on PARP Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2020-2031)
3.6.3 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Cancer Drug based on PARP Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2020-2031)
3.7.3 Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2020-2031)
3.8.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2020-2031)
4.1.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2020-2025)
4.1.2 Global Cancer Drug based on PARP Inhibitor Sales by Type (2026-2031)
4.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2020-2031)
4.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2020-2031)
4.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2020-2025)
4.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2026-2031)
4.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2020-2031)
4.3 Global Cancer Drug based on PARP Inhibitor Price by Type (2020-2031)
5 Segment by Application
5.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2020-2031)
5.1.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2020-2025)
5.1.2 Global Cancer Drug based on PARP Inhibitor Sales by Application (2026-2031)
5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2020-2031)
5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2020-2031)
5.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2020-2025)
5.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2026-2031)
5.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2020-2031)
5.3 Global Cancer Drug based on PARP Inhibitor Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Company Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Clovis Oncology
6.4.1 Clovis Oncology Company Information
6.4.2 Clovis Oncology Description and Business Overview
6.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio
6.4.5 Clovis Oncology Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Zai Lab
6.6.1 Zai Lab Company Information
6.6.2 Zai Lab Description and Business Overview
6.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio
6.6.5 Zai Lab Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Drug based on PARP Inhibitor Industry Chain Analysis
7.2 Cancer Drug based on PARP Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Drug based on PARP Inhibitor Production Mode & Process Analysis
7.4 Cancer Drug based on PARP Inhibitor Sales and Marketing
7.4.1 Cancer Drug based on PARP Inhibitor Sales Channels
7.4.2 Cancer Drug based on PARP Inhibitor Distributors
7.5 Cancer Drug based on PARP Inhibitor Customer Analysis
8 Cancer Drug based on PARP Inhibitor Market Dynamics
8.1 Cancer Drug based on PARP Inhibitor Industry Trends
8.2 Cancer Drug based on PARP Inhibitor Market Drivers
8.3 Cancer Drug based on PARP Inhibitor Market Challenges
8.4 Cancer Drug based on PARP Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Merck
GSK
Clovis Oncology
Pfizer Inc
ZAI LAB
List of Tables
 Table 1. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Cancer Drug based on PARP Inhibitor Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Cancer Drug based on PARP Inhibitor Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Cancer Drug based on PARP Inhibitor Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Cancer Drug based on PARP Inhibitor Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Cancer Drug based on PARP Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Type & Application
 Table 12. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug based on PARP Inhibitor as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Cancer Drug based on PARP Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Cancer Drug based on PARP Inhibitor Sales by Region (2020-2025) & (K Units)
 Table 18. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2020-2025)
 Table 19. Global Cancer Drug based on PARP Inhibitor Sales by Region (2026-2031) & (K Units)
 Table 20. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2026-2031)
 Table 21. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2020-2025)
 Table 23. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2026-2031)
 Table 25. North America Cancer Drug based on PARP Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Cancer Drug based on PARP Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 27. North America Cancer Drug based on PARP Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 28. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Cancer Drug based on PARP Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Type (2020-2025)
 Table 51. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Type (2026-2031)
 Table 52. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2020-2025)
 Table 53. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2026-2031)
 Table 54. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2020-2025)
 Table 57. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2026-2031)
 Table 58. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Application (2020-2025)
 Table 61. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Application (2026-2031)
 Table 62. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2020-2025)
 Table 63. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2026-2031)
 Table 64. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2020-2025)
 Table 67. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2026-2031)
 Table 68. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Application (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca Cancer Drug based on PARP Inhibitor Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Merck & Co Company Information
 Table 76. Merck & Co Description and Business Overview
 Table 77. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck & Co Cancer Drug based on PARP Inhibitor Product
 Table 79. Merck & Co Recent Developments/Updates
 Table 80. GSK Company Information
 Table 81. GSK Description and Business Overview
 Table 82. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. GSK Cancer Drug based on PARP Inhibitor Product
 Table 84. GSK Recent Developments/Updates
 Table 85. Clovis Oncology Company Information
 Table 86. Clovis Oncology Description and Business Overview
 Table 87. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Clovis Oncology Cancer Drug based on PARP Inhibitor Product
 Table 89. Clovis Oncology Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Cancer Drug based on PARP Inhibitor Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Zai Lab Company Information
 Table 96. Zai Lab Description and Business Overview
 Table 97. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Zai Lab Cancer Drug based on PARP Inhibitor Product
 Table 99. Zai Lab Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Cancer Drug based on PARP Inhibitor Distributors List
 Table 103. Cancer Drug based on PARP Inhibitor Customers List
 Table 104. Cancer Drug based on PARP Inhibitor Market Trends
 Table 105. Cancer Drug based on PARP Inhibitor Market Drivers
 Table 106. Cancer Drug based on PARP Inhibitor Market Challenges
 Table 107. Cancer Drug based on PARP Inhibitor Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Cancer Drug based on PARP Inhibitor
 Figure 2. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Cancer Drug based on PARP Inhibitor Market Share by Type: 2024 & 2031
 Figure 4. Lynparza Product Picture
 Figure 5. Zejula Product Picture
 Figure 6. Rubraca Product Picture
 Figure 7. Talzenna Product Picture
 Figure 8. Global Cancer Drug based on PARP Inhibitor Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Cancer Drug based on PARP Inhibitor Market Share by Application: 2024 & 2031
 Figure 10. Ovarian Cancer
 Figure 11. Breast Cancer
 Figure 12. Other
 Figure 13. Global Cancer Drug based on PARP Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Cancer Drug based on PARP Inhibitor Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Cancer Drug based on PARP Inhibitor Sales (2020-2031) & (K Units)
 Figure 16. Global Cancer Drug based on PARP Inhibitor Average Price (US$/Unit) & (2020-2031)
 Figure 17. Cancer Drug based on PARP Inhibitor Report Years Considered
 Figure 18. Cancer Drug based on PARP Inhibitor Sales Share by Manufacturers in 2024
 Figure 19. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Cancer Drug based on PARP Inhibitor Players: Market Share by Revenue in Cancer Drug based on PARP Inhibitor in 2024
 Figure 21. Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Cancer Drug based on PARP Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2020-2031)
 Figure 24. North America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 25. United States Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2020-2031)
 Figure 28. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2020-2031)
 Figure 36. China Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Cancer Drug based on PARP Inhibitor by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Cancer Drug based on PARP Inhibitor by Type (2020-2031)
 Figure 57. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Cancer Drug based on PARP Inhibitor by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Cancer Drug based on PARP Inhibitor by Application (2020-2031)
 Figure 60. Global Cancer Drug based on PARP Inhibitor Price (US$/Unit) by Application (2020-2031)
 Figure 61. Cancer Drug based on PARP Inhibitor Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

PARP Inhibitors for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PARP Poly ADP ribose Polymerase Inhibitors Market Insights Forecast to 2030
Global Enzyme Poly ADP Ribose Polymerase PARP Inhibitor Market Insights Forecast to 2030
Prostate Cancer PARP Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PARP Poly ADP Ribose Polymerase Inhibitor Market Research Report 2025
Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market Insights Forecast to 2030
Global Poly ADP Ribose Polymerase PARP Inhibitors Market Research Report 2024
Global PARP Inhibitors for Breast Cancer Market Research Report 2024
DNA Repair PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
PD L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Small Molecule Inhibitors for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Platinum Anti tumor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Niraparib API Market Research Report 2024
Global Breast Cancer Drugs Market Insights Forecast to 2030
Global Niraparib Preparations Market Research Report 2024
Global Olaparib API Market Research Report 2024
Global Kinase Inhibitors Market Insights Forecast to 2030
Global PARP Inhibitor Biomarkers Testing Product Market Research Report 2024
Targeting DNA Repair Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Molecular Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions